Mednet Logo
Community

Will you incorporate immunotherapy in neoadjuvant treatment of triple negative breast cancer based off KEYNOTE-522?

Based on pCR and EFS data from KEYNOTE 522 and recent FDA approval?
2 Answers
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Baptist Health South Florida
Answered on

Insurance issues aside, I would incorporate immunotherapy into neoadjuvant triple negative therapy. I participated in this trial and I am aware of the pathologic complete response data. I suspect that this could lead, ultimately, to FDA approval. In the meantime, if feasible, I would use the Keynote...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Medical Oncology · University of Colorado Cancer Center
Answered on

Yes.
T2 or greater.
Questions remain: is carboplatin truly necessary for all patients? Do patients who achieve pCR need adjuvant pembrolizumab?

Join for free or sign in to see the full answer